Prognosis of ocular myasthenia in Korea: A retrospective multicenter analysis of 202 patients

Journal of the Neurological Sciences

Volumn 273, Issue 1-2, 2008, Pages 10-14

  Hong, Yoon Ho ^a   Kwon, Seok Beom ^b   Kim, Byung Jo ^c   Kim, Byoung Joon ^d   Kim, Seung Hyun ^e   Kim, Jong Kuk ^f   Park, Kyung Seok ^g   Park, Ki Jong ^h   Sung, Jung Joon ⁱ   Sohn, Eun Hee ^j   Lee, Yeong Bae ^k   Jeong, Dushin ^l   Joo, In Soo ^m   Choi, Byung Ok ⁿ   Choi, Young Chul ^o  

^a Seoul National University Boramae Hospital   (South Korea)

^b Hallym University   (South Korea)

^c Korea University Ansan Hospital   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Hanyang University College of Medicine   (South Korea)

^f Kosin University   (South Korea)

^g Seoul National University Bundang Hospital   (South Korea)

^h Gyeongsang National University   (South Korea)

ⁱ Seoul National University Hospital   (South Korea)

^j Chungnam National University College of Medicine   (South Korea)

^k Gachon University College of Medicine   (South Korea)

^l Soonchunhyang University   (South Korea)

^m Ajou University Medical Center   (South Korea)

ⁿ Mokdong Hospital   (South Korea)

^o Yonsei University   (South Korea)

more..

Author keywords

AChR antibody; Ocular myasthenia gravis; Prognosis; Repetitive nerve stimulation test; Thymoma

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; PREDNISOLONE;

ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; EYE DISEASE; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; KOREA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; NERVE STIMULATION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; THYMECTOMY; THYMOMA;

ADULT; AGED; AGED, 80 AND OVER; AGING; ANALYSIS OF VARIANCE; FEMALE; HUMANS; KOREA; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PROGNOSIS; RECEPTORS, CHOLINERGIC; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 50049090027     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.05.023     Document Type: Article

References (22)

1. Jaretzki III A., Barohn R.J., Ernstoff R.M., Kirkham T.H., Knox D.L., Miller N.R., et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55 (2000) 16-23
2. Bever C.T., Aquino A.V., Penn A.S., Lovelace R.E., and Rowland L.P. Prognosis of ocular myasthenia. Ann Neurol 14 (1983) 516-519
3. Oosterhuis H.J. The natural course of myasthenia gravis: a longterm follow-up study. J Neurol Neurosurg Psychiatry 52 (1989) 1121-1127
4. Sommer N., Sigg B., Melms A., Weller M., Schepelmann K., Herzau V., et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 62 (1997) 156-162
5. Papapetropoulous T.H., Ellul J., and Tsibri E. Development of generalized myasthenia gravis in patients with ocular myasthenia. Arch Neurol 60 (2003) 1491-1492
6. Mee J., Paine M., Byrne E., King J., Reardon K., and O'Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroopthalmol 23 (2003) 251-255
7. Kupersmith M.J., Latkany R., and Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 60 (2003) 243-248
8. Monsul N.T., Patwa H.S., Knorr A.M., Lesser R.L., and Goldstein J.M. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 217 (2004) 131-133
9. Benatar M., and Kaminski H.J. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 68 (2007) 2144-2149
10. Uono M. Clinical statistics of myasthenia gravis in Japan. Int J Neurol 14 (1980) 87-99
11. Chan-Lui W.Y., Leung N.K., and Lau T.T.Y. Myasthenia gravis in Chinese children. Dev Med Child Neurol 26 (1984) 717-724
12. Chiu H.C., Vincent A., Newsom-Davis J., Hsieh K.H., and Hung T.P. Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians. Neurology 37 (1987) 1854-1857
13. Lee K.W., Kim J.S., Lee S.H., and and MG Study Group. Epidemiological and clinical characteristics of myasthenia gravis in Korea. J Korean Neurol Assoc 15 (1997) 825-838
14. Yu Y.L., Hawkins B.R., Ip M.S.M., Wong V., and Woo E. Myasthenia gravis in Hong Kong Chinese. 1. Epidemiology and adult disease. Acta Neurol Scand 86 (1992) 113-119
15. Kupersmith M.J. Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease?. J Neurol Sci 217 (2004) 123-124
16. Grob D., Arsura E.L., Brunner N.G., and Nambda T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 505 (1987) 472-499
17. Evoli A., Tonali P., Bartoccioni E., and Lo Monaco M. Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol Scand 77 (1988) 31-35
18. Sommer N., Melms A., Weller M., and Dichgans J. Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects. Doc Ophthalmol 84 (1993) 309-333
19. Vincent A., and Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 48 (1985) 1246-1252
20. Moorthy G., Behrens M.M., Drachman D.B., Kirkham T.H., Knox D.L., Miller N.R., et al. Ocular pseudomyasthenia or ocular myasthenia "plus": a warning to clinicians. Neurology 39 (1989) 1150-1154
21. Thomas M., Ahuja G.K., Behari M., and Prasad K. Ocular myasthenia gravis-factors predictive for generalisation. J Assoc Phys India 41 (1993) 28-29
22. Weimberg D.H., Rizzo J.F., Hayes M.T., Kneeland M.D., and Kelly J.J. Ocular myasthenia gravis: predictive value of single-fiber electromyography. Muscle Nerve 22 (1999) 1222-1227